GYRE Stock Summary and Trading Ideas (Gyre Therapeutics | NASDAQ:GYRE)

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Gyre Therapeutics trades on the NASDAQ stock market under the symbol GYRE.

As of April 9, 2025, GYRE stock price declined to $6.66 with 203,261 million shares trading.

GYRE has a beta of 2.05, meaning it tends to be more sensitive to market movements. GYRE has a correlation of 0.19 to the broad based SPY ETF.

GYRE has a market cap of $623.46 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that GYRE belongs to (by Net Assets): VXF, IWM, SCHA, IWN, VTWO.

GYRE has underperformed the market in the last year with a price return of -60.5% while the SPY ETF lost -2.3%. GYRE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -30.8% and -29.8%, respectively, while the SPY returned -14.9% and -13.2%, respectively.

GYRE support price is $6.54 and resistance is $7.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GYRE shares will trade within this expected range on the day.